Ultragenyx Pharmaceutical Inc. RARE

Latest FY: 2025 Healthcare Biotechnology
Market Price $14.84
Market Cap $1.46B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑20.1% YoY
$673.00M
3-Yr CAGR: 22.8%
Net Income ↓-1.0% YoY
-$575.00M
Net Margin: -85.4%
Free Cash Flow ↓-11.9% YoY
-$472.00M
FCF Yield: -32.29%
EPS (Diluted) ↑7.3% YoY
$-5.83
Basic: $-5.83
Return on Equity Efficiency
N/A
ROA: -37.5%
⚡ N/A due to negative equity (share buybacks or other)

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (RARE)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $0.1M $-183.1M $-245.9M $-161.0M $-171.2M
FY 2017 $2.6M +1,863.9% $2.6M $-302.1M -22.9% $-253.8M $-256.6M -49.9%
FY 2018 $51.5M +1,871.5% $50.3M $-197.6M +34.6% $-290.6M $-294.6M -14.8%
FY 2019 $103.7M +101.4% $-262.6M $-402.7M -103.8% $-345.4M $-370.2M -25.6%
FY 2020 $271.0M +161.3% $-147.2M $-186.6M +53.7% $-3.07 $-132.2M $-176.1M +52.4%
FY 2021 $351.4M +29.7% $-161.8M $-454.0M -143.4% $-6.70 -118.2% $-338.7M $-411.8M -133.8%
FY 2022 $363.3M +3.4% $-370.8M $-707.4M -55.8% $-10.12 -51.0% $-380.5M $-496.6M -20.6%
FY 2023 $434.2M +19.5% $-259.4M $-606.6M +14.2% $-8.25 +18.5% $-474.8M $-519.1M -4.5%
FY 2024 $560.2M +29.0% $-214.4M $-569.2M +6.2% $-6.29 +23.8% $-414.2M $-421.7M +18.8%
FY 2025 $673.0M +20.1% $-186.0M $-575.0M -1.0% $-5.83 +7.3% $-466.0M $-472.0M -11.9%
$

Valuation

Market Price $14.84
Market Cap $1.46B
Enterprise Value $1.04B
P/E Ratio N/A
P/B Ratio N/A
FCF Yield -32.29%
Dividend Yield N/A
Shares Outstanding 98,489,200
%

Profitability & Margins

Gross Margin -27.64%
Operating Margin -79.49%
Net Margin -85.44%
Return on Equity (ROE) N/A (Negative Equity)
Return on Assets (ROA) -37.53%
Asset Turnover 0.44x
Revenue 3-Yr CAGR 22.81%
🛡️

Financial Health & Liquidity

Current Ratio 2.48
Cash Ratio 1.10
Debt / Equity -0.000
Debt / Assets 0.000
Cash & Equivalents $421.00M
Total Debt N/A
Book Value / Share $-0.81
💧

Cash Flow Efficiency

Operating Cash Flow -$466.00M
Capital Expenditures (CapEx) $6.00M
Free Cash Flow -$472.00M
OCF / Revenue -69.24%
FCF / Revenue -70.13%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-5.83
EPS (Basic) $-5.83
Dividends / Share N/A
Book Value / Share $-0.81
EPS YoY Growth 7.31%
🏛️

Balance Sheet (FY 2025)

Total Assets $1.53B
Total Liabilities $1.60B
Stockholders' Equity -$80.00M
Current Assets $951.00M
Current Liabilities $384.00M